The Study
Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts
This study looked at how a drug-like substance moves into cells in a lab dish. It shows that the substance might use a specific doorway in the cells, but it doesn’t prove it will work in people or treat disease.
Analysis score
Maximum 44 for a cross-sectional study.
Where the score came from
Scientists wanted to see how a medicine called cyclocreatine gets into brain-related cells. They tested it in lab-grown cells and cells from patients who can't move creatine into their brains.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 54 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This suggests cyclocreatine could work as a replacement for creatine in people with a broken creatine transporter, potentially helping treat brain disorders.
- 2Cyclocreatine enters cells the same way as creatine.
- 3When the transporter is broken, both get in much less.
- 4This happened in normal cells when the transporter was blocked and in patient cells with a faulty transporter.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Pharmaceutical Research
Year
2020
Authors
Tatsuki Uemura, S. Ito, Takeshi Masuda, Hiroko Shimbo, T. Goto, H. Osaka, T. Wada, P. Couraud, S. Ohtsuki
Related Content
Claims (4)
Cells use a special pump to create a sodium imbalance outside and inside the cell, and that imbalance acts like a battery to help pull creatine into the cell through a specific door called SLC6A8.
Cyclocreatine gets into brain-like cells in a lab mainly using a special doorway called the creatine transporter — when scientists block or remove this doorway, less cyclocreatine gets in, suggesting it relies on that path.
In people with a rare brain disorder caused by a broken creatine transporter, their cells don't take in creatine or a similar molecule called cyclocreatine as well — showing the broken transporter affects both in the same way.
Cyclocreatine gets into kidney cells in a way that looks like it's being actively carried in, not just drifting in on its own—kind of like being carried through a door instead of seeping through a wall.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.